Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).

被引：0
|
作者：
Mohr, Peter
Hauschild, Axel
Trefzer, Uwe
Enk, Alexander
Tilgen, Wolfgang
Loquai, Carmen
Gogas, Helen
Haalck, Thomas
Koller, Josef
Schadendorf, Dirk
Dummer, Reinhard
Gutzmer, Ralf
Brockmeyer, Norbert
Hoelzle, Erhard
Sunderkoetter, Cord
Mauch, Cornelia
Stein, Anette
Schneider, Lars
Podda, Maurizio
Weichenthal, Michael
机构：
[1] Elbe Klinikum Buxtehude, Buxtehude, Germany
[2] Univ Klinikum Schleswig Holstein, Kiel Schleswig Holstein, Germany
[3] Charite, Melanomactr, D-13353 Berlin, Germany
[4] Heidelberg Univ, Hautklin, Heidelberg, Germany
[5] Univ Dept Dermatol, Homburg, Germany
[6] Univ Dept Dermatol, Mainz, Germany
[7] Hellen Cooperat Oncol Grp, Athens, Greece
[8] Univ Dept Dermatol, Hamburg, Germany
[9] Landesklin Dermatol, Salzburg, Austria
[10] Univ Hosp Essen, Essen, Germany
[11] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
[12] Hannover Med Sch, Skin Canc Ctr, Dept Dermatol & Allergy, Hannover, Germany
[13] Univ Dept Dermatol, Bochum, Germany
[14] Dept Dermatol, Oldenburg, Germany
[15] Univ Dept Dermatol, Munster, Germany
[16] Univ Cologne, D-50931 Cologne, Germany
[17] Dept Dermatol, Dresden, Germany
[18] Univ Dept Dermatol, Ulm, Germany
[19] Dept Dermatol, Darmstadt, Germany
[20] Univ Dept Dermatol, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8505
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Concurrent adjuvant radiotherapy and interferon-α2b for resected high risk stage III melanoma -: a retrospective single centre study
    Gyorki, DE
    Ainslie, J
    Joon, ML
    Henderson, MA
    Millward, M
    McArthur, GA
    [J]. MELANOMA RESEARCH, 2004, 14 (03) : 223 - 230
  • [32] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
  • [33] A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
    Mao, Lili
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Li, Siming
    Tang, Bixia
    Guo, Jun
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1498 - 1503
  • [34] RANDOMIZED PHASE-III TRIAL OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED MELANOMA
    SPARANO, JA
    FISHER, RI
    SUNDERLAND, M
    MARGOLIN, K
    ERNEST, ML
    SZNOL, M
    ATKINS, MB
    DUTCHER, JP
    MICETICH, KC
    WEISS, GR
    DOROSHOW, JH
    ARONSON, FR
    RUBINSTEIN, LV
    MIER, JW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) : 1969 - 1977
  • [35] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Testori, Alessandro
    Santinami, Mario
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Dummer, Reinhard
    Robert, Caroline
    Schadendorf, Dirk
    Patel, Poulam M.
    de Schaetzen, Gaetan
    Spatz, Alan
    Keilholz, Ulrich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818
  • [36] High-dose interferon-alpha(2b) for re-treatment of nonresponders or relapsing patients with chronic hepatitis C - A controlled randomized trial
    Bonkovsky, HL
    Clifford, BD
    Smith, LJ
    Allan, C
    Banner, B
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (01) : 149 - 154
  • [37] Health related quality of life in the Nordic randomized trial of adjuvant intermediate-dose interferon α-2b in high-risk melanoma
    Brandberg, Yvonne
    Aamdal, Steinar
    Bastholt, Lars
    Hernberg, Micaela
    Stierner, Ulrika
    von der Maase, Hans
    Hansson, Johan
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 278 - 278
  • [38] Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
    Lian, Bin
    Si, Lu
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Mao, Lili
    Li, Siming
    Kong, Yan
    Tang, Bixia
    Guo, Jun
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4488 - 4498
  • [39] Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma:: An Eastern Cooperative Oncology Group study
    Falkson, CI
    Ibrahim, J
    Kirkwood, JM
    Coates, AS
    Atkins, MB
    Blum, RH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1743 - 1751
  • [40] Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial
    Hauschild, A.
    Volkenandt, M.
    Tilgen, W.
    Linse, R.
    Boettjer, J.
    Vogt, T.
    Spieth, K.
    Eigentler, T.
    Brockmeyer, N. H.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345